Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Public ClinicalTrials.gov record NCT00111839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Disease on or After First-Line Treatment With a Platinum in Combination With Taxanes, Gemcitabine and Vinorelbine
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal antibody, with a chemotherapy treatment, called pemetrexed.
Study identification
- NCT ID
- NCT00111839
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 150 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2005 (Actual)
- Primary completion
- Jul 31, 2007 (Actual)
- Completion
- Mar 31, 2009 (Actual)
- Last update posted
- Apr 6, 2018
2005 – 2009
United States locations
- U.S. sites
- 42
- U.S. states
- 26
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Clinical Research Center | Tucson | Arizona | 85715 | — |
| University of Arkansas, Arkansas Cancer Research Center | Little Rock | Arkansas | 72205 | — |
| University of Southern California/Norris Cancer Center | Los Angeles | California | 90033 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Integrated Community Oncology Network | Jacksonville | Florida | 32256 | — |
| Cancer Center or Florida | Ocoee | Florida | 34761 | — |
| Peachtree Hematology and Oncology | Atlanta | Georgia | 30309 | — |
| Georgia Cancer Specialists | Tucker | Georgia | 30084 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| University of Illinois | Chicago | Illinois | 60612 | — |
| Cancer Care Specialists of Central Illinois | Decatur | Illinois | 62256 | — |
| Cancer Institute of Alexian Brothers | Elk Grove Village | Illinois | 60007 | — |
| Indiana Oncology Hematology Consultants | Indianapolis | Indiana | 46202 | — |
| Hematology-Oncology of Indiana PC | Indianapolis | Indiana | 46260 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| Kansas City Cancer Center | Overland Park | Kansas | 66210 | — |
| Louisville Oncology | Louisville | Kentucky | 40202 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40402 | — |
| Hematology-Oncology Clinic | Baton Rouge | Louisiana | 70808 | — |
| Frederick Memorial Hospital | Frederick | Maryland | 21701 | — |
| Tuffs-New England Medical Center | Boston | Massachusetts | 20111 | — |
| Henry Ford Health Systems | Detroit | Michigan | 48202 | — |
| West Michigan Regional Cancer and Blood Center | Free Soil | Michigan | 49411 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| University of Missouri | Columbia | Missouri | 65203 | — |
| Deaconess Billings Clinic | Billings | Montana | 59101 | — |
| Nebraska Hematology-Oncology, PC | Lincoln | Nebraska | 68506 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| New York Oncology | Albany | New York | 12208 | — |
| University of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Presbyterian Hospital Cancer Center | Charlotte | North Carolina | 28204 | — |
| The Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Dayton Oncology and Hematology | Kettering | Ohio | 45409 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Hematology & Oncology Associates of NEPA | Dunmore | Pennsylvania | 19107 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Mary Crowley Research Center | Dallas | Texas | 75246 | — |
| Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Rainer Oncology Professional Services | Puyallup | Washington | 98372 | — |
| Cancer Care Northwest | Spokane | Washington | 99218 | — |
| University of Wisconsin | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00111839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2018 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00111839 live on ClinicalTrials.gov.